Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Differentiated by Clinical Trials, World-Class Management

Rhea-AI Summary

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is advancing its Psilocybin-for-Neuropsychiatric Disorders (PFN) program into Phase 2a clinical trials, setting the stage for potential breakthroughs in treatments for fibromyalgia and eating disorders. The company differentiates itself by exploring a wider range of neuropsychiatric indications compared to its peers. With its lead candidate, TRP-8802, and a new proprietary formulation, TRP-8803, Tryp aims to leverage the therapeutic potential of psilocybin.

Positive

• Advancement of PFN program into Phase 2a clinical trials.
• Unique focus on diverse neuropsychiatric conditions beyond standard mental health issues.
• Partnership with University of Florida for eating disorders study.

Negative

• None.

News Market Reaction – TRYPF

+3.97%

1 alert

+3.97% News Effect

On the day this news was published, TRYPF gained 3.97%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, July 01, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “GW Pharma Sells for Bilions; Psychedelic Company Following Similar Path.”

To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast

To view the full editorial, please visit: https://nnw.fm/0N5t5

Many companies are angling to capitalize on the emergence of psychedelics for therapeutic indications, but only a select few pharmaceutical companies are entering Phase 2a clinical trials, including Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF). Tryp’s pipeline is comprised of its Psilocybin-for-Neuropsychiatric Disorders, or PFN, program that includes TRP-8802, the initial oral formulation of psilocybin for Tryp’s Phase 2a clinical trials, and TRP-8803, a proprietary formulation with novel method of administration planned to be used for Phase 2a trials.

With world-class management and advisors, Tryp is advancing its PFN program into Phase 2a clinical studies, a derisking factor not seen in most peers. Furthermore, Tryp is differentiated by evaluating indications outside the limited mental health conditions that others in the space are pursuing.

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and safety profiles for the treatment of rare and other diseases with unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than five million people in the United States. The company is also preparing to initiate a phase 2a clinical study for eating disorders in partnership with the Dr. Jennifer Miller at the University of Florida. In addition to its PFN program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft-tissue sarcoma. Soft-tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children. Based on the prevalence of soft-tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for orphan drug status.

For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYP are available in the company’s newsroom at https://ibn.fm/TRYPF.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only).

For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website, applicable to all content provided by NNW wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

FAQ

What are the clinical trials for Tryp Therapeutics' TRP-8802?

TRP-8802 is in Phase 2a clinical trials targeting fibromyalgia, a condition affecting over five million people in the U.S.

When did Tryp Therapeutics announce the Phase 2a clinical trials?

Tryp announced the advancement into Phase 2a clinical trials on July 1, 2021.

What is the market potential of Tryp Therapeutics' PFN program?

The PFN program aims to address significant unmet medical needs in neuropsychiatric disorders, potentially tapping into a large market.

What is the significance of TRYPF stock related to Tryp Therapeutics?

TRYPF represents Tryp Therapeutics on OTC markets, reflecting investor interest in its innovative approaches to treating neuropsychiatric conditions.